

PRESS RELEASE- FOR IMMEDIATE RELEASE

## IntegraGen – Appointment of Laurence Riot Lamotte as Chief Financial Officer

---

**EVRY, THURSDAY 8<sup>TH</sup> DECEMBER 2011 - IntegraGen**, a leading player in the development and commercialization of molecular diagnostic tests in the field of Autism and Oncology, today announces the appointment of Laurence Riot Lamotte as Chief Financial Officer.

Laurence Riot Lamotte began her career in Deloitte's Audit department before joining Thomson, where she held various job positions over ten years, firstly in international operations and then within the "Strategic Finance" department. She then managed several development projects for Deutsche Telekom's French subsidiary.

Prior to joining IntegraGen, since 2004 Laurence Riot Lamotte was CFO of Aureus Sciences, a software publisher in the field of pharmaceutical research, and LBMA (Laboratoire de Biotechnologies Marines Appliquées), where she gained substantial experience of the health sector.

Laurence Riot Lamotte is a graduate of the CESEM management school (RMS group) and holds a German "Diplombetriebswirt", as well as a Masters degree in Telecoms and New Media from Paris-Dauphine University.

**Bernard Courtieu**, Chief Executive Officer, comments: "*We are delighted to welcome Laurence Riot Lamotte to our teams. Laurence has substantial international experience, considerable knowledge of the health sector and developed, in her previous jobs, solid expertise in mergers and acquisitions, raising capital and investor relations. Furthermore, she is driven by a strong entrepreneurial spirit. All these qualities will be valuable assets to accompany IntegraGen through its ambitious growth plan, in Europe and the United States.*"

### **ABOUT INTEGRAGEN**

IntegraGen is a biotechnology company dedicated to gene discovery with the goal of developing molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen, and its wholly owned U.S. subsidiary IntegraGen, Inc., are focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen's Genetic Services Business also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on autism and oncology, IntegraGen's core strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

As of 31<sup>st</sup> December 2010, IntegraGen's headcount was 25. The company recorded FY sales of €3.2m from its Services activity. IntegraGen's headquarters are in Evry, France (Genopole – 91). IntegraGen inc., the US subsidiary, is based in Cambridge, MA.

IntegraGen is listed on Alternext, NYSE Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT)  
More information on IntegraGen's website: [www.integragen.com](http://www.integragen.com)

## CONTACTS



### **INTEGRAGEN**

Bernard Courtieu  
CEO  
Tel.: +33 (0)1 60 91 09 00

Laurence Riot Lamotte  
CFO  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 09

### *NEWCAP.*

#### **Investor and media relations**

Axelle Vuillermet  
[integragen@newcap.fr](mailto:integragen@newcap.fr)  
Tel.: +33 (0)1 44 71 94 93